Back to Journals » Therapeutics and Clinical Risk Management » Current and Emerging Strategies in the Management of Cardiac Arrhythmias
Therapeutics and Clinical Risk Management
- View all (2615)
- Volume 22, 2026 (59)
- Volume 21, 2025 (162)
- Volume 20, 2024 (86)
- Volume 19, 2023 (91)
- Volume 18, 2022 (104)
- Volume 17, 2021 (134)
- Volume 16, 2020 (134)
- Volume 15, 2019 (154)
- Volume 14, 2018 (271)
- Volume 13, 2017 (188)
- Volume 12, 2016 (217)
- Volume 11, 2015 (210)
- Volume 10, 2014 (113)
- Volume 9, 2013 (57)
- Volume 8, 2012 (47)
- Volume 7, 2011 (59)
- Volume 6, 2010 (66)
- Volume 5, 2009 (102)
- Volume 4, 2008 (148)
- Volume 3, 2007 (126)
- Volume 2, 2006 (47)
- Volume 1, 2005 (40)
Journal Articles:
- Older and newer players in the therapeutics of Cardio-Kidney-Metabolic syndrome (1)
- Machine Learning in the Realm of Therapeutics and Clinical Risk Management (1)
- Lymphoproliferation at the crossroad between hematology and immunology: molecular and clinical implications (1)
- Anticholinergic Therapies for the Treatment of Asthma (7)
Current and Emerging Strategies in the Management of Cardiac Arrhythmias
Cardiac arrhythmias remain a major cause of morbidity, mortality, hospitalization, and impaired quality of life worldwide. They encompass a broad and increasingly complex spectrum of disorders, ranging from atrial fibrillation and supraventricular tachycardias to ventricular arrhythmias, conduction disease, and inherited arrhythmic syndromes. Over the past few years, the field has evolved rapidly, driven by major advances in catheter ablation technologies, physiological pacing, multimodality imaging, digital diagnostics, and data-enabled clinical decision-making.
